Selected article for: "activity monitoring and long term disability"
Author: Wieske, Luuk; Smyth, Duncan; Lunn, Michael P.; Eftimov, Filip; Teunissen, Charlotte E.
Title: Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
  • Cord-id: 5s36242n
  • Document date: 2021_10_18
    • ID: 5s36242n
    Snippet: Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidat
    Document: Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-021-01136-0.

    Search related documents:
    Co phrase search for related documents
    • acidic protein and acute phase: 1, 2, 3
    • acidic protein and acute severe: 1, 2, 3, 4, 5
    • acidic protein and longitudinal study: 1
    • active disease and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active disease and acute phase: 1, 2, 3, 4, 5
    • active disease and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active disease and long term outcome: 1, 2
    • active disease and longitudinal study: 1, 2
    • active disease patient and acute disease: 1
    • active disease patient and acute severe: 1, 2, 3
    • acute disease and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute disease and long term prognosis: 1, 2, 3
    • acute disease and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute disease and low baseline serum level: 1
    • acute phase and long term outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute phase and long term prognosis: 1
    • acute phase and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute severe and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute severe and longitudinal study conduct: 1, 2